MicroRNA profiling of breast cancer tissue using an LNA-based microarray

Abnormal expression of microRNAs (miRNAs) in cancer suggests their applicability as diagnostic and prognostic signatures. Here we describe a new microarray platform, miRCURY™ LNA, based on Locked Nucleic Acid (LNA™)-modified capture probes that have uniquely high affinities for miRNAs. We applied this platform to study the global expression profiles of miRNAs in breast cancer with the aim of identifying potential new biomarkers.